ANURASBSEAnupam Rasayan India LtdHighPositive
Announced Sat, 23 May · 20:59 IST

Intimation of Press Release titled "Anupam Rasayan India Limited enters into a definitive agreement to acquire 43.3-48.2% equity stake + open offer to the public shareholders of Bliss GVS ....

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF

ANURAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹1359.00
prior close
₹1390.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.1-3.0-3.1-3.4+0.8+0.3-5.0-2.6-2.8-1.0-7.6-6.6-10.5
Up moveDown movePending
AI summary

Anupam Rasayan India Limited has entered into a definitive agreement to acquire a 43.3%-48.2% equity stake in Bliss GVS Pharma Limited, a listed pharmaceutical formulations company. The company will also make an Open Offer to the remaining public shareholders of Bliss GVS Pharma. The total purchase consideration is being financed through Rs 300 Crores via Term Loan and the balance through non-controlling non-voting equity instruments. Bliss GVS Pharma is engaged in developing, manufacturing, and exporting pharmaceutical dosage forms including suppositories, tablets, capsules, and injectables, with EU-GMP and US FDA approved manufacturing facilities in Maharashtra and Daman. The acquisition aims to create an integrated pharmaceutical platform spanning from KSMs to finished dosage formulations.

Likely market impact

This acquisition positions Anupam Rasayan to expand from specialty chemicals into the broader pharmaceutical value chain, gaining access to regulated markets in Europe and America. The Open Offer may result in further stake buildup and could impact Bliss GVS Pharma's shareholding structure significantly.